Ruibai Li
Overview
Explore the profile of Ruibai Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li R, Xue C, Pan Y, Li G, Huang Z, Xu J, et al.
J Ethnopharmacol
. 2024 Feb;
326:117778.
PMID: 38310990
Ethnopharmacological Relevance: In China, the Chinese patent drug Realgar-Indigo naturalis Formula (RIF) is utilized for the therapy of acute promyelocytic leukemia (APL). Comprising four traditional Chinese herb-Realgar, Indigo naturalis, Salvia...
2.
Li G, Wu J, Li R, Pan Y, Ma W, Xu J, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Dec;
23(2):e78-e84.
PMID: 36567214
Background: Early death is a major factor of treatment failure in acute promyelocytic leukemia (APL), however, the recent trends in the incidence of early death based on the population-level are...
3.
Pan Y, Chen L, Li R, Liu Y, Nan M, Hou L
Evid Based Complement Alternat Med
. 2021 Oct;
2021:3372403.
PMID: 34691211
Tanshinone IIa (TanIIa), an ingredient of Radix Salviae Miltiorrhizae, has an anticancer effect on various solid tumors with high efficiency and low toxicity. Nonetheless, the underlying role of TanIIa in...
4.
Han R, Chen X, Li Y, Zhang S, Li R, Lu L
Cancer Manag Res
. 2019 May;
11:2963-2976.
PMID: 31114344
Accumulating evidence suggests an antineoplastic role of () in human cancer. However, its precise biological functions stay largely elusive. Our study was aimed to investigate the impact of on hepatocellular...
5.
Gao C, Wang J, Li Y, Zhao H, Li R, Hou L, et al.
Medicine (Baltimore)
. 2018 Aug;
97(34):e11860.
PMID: 30142779
Background: Hypomethylating agents (HMAs) are believed to have reliable efficacy in treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Meanwhile, the adverse events of HMAs have become an increasing...